Biocius and BlueSky to Develop Sirtuin Enzymes Validated Using Label-Free Assays

The collaboration, which builds on an existing partnership between the two companies, has the potential to improve the drug discovery efficiency of SIRT epigenetic modulating enzymes, which have been implicated in processes such as insulin signaling, apoptosis, and cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.